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Abstract  
Introduction                
Warfarin therapy is stopped for a fixed period prior to surgery to minimise risk of 
perioperative bleeding. However, anticoagulation subsides at varying rates among different 
patients. We evaluated the influence of genetic (CYP2C9 and VKORC1), patient and clinical 
factors on warfarin clearance and the decline in INR following warfarin withdrawal.  
Materials and methods                                                                                                          
131 patients completing a course of warfarin provided blood samples over 9 days for initial 
genotyping, and measurement of INR and plasma warfarin enantiomer concentrations.  
Results                                                                                                                                     
S-warfarin clearance was significantly lower in patients with either CYP2C9 single (*2 or *3) 
or double (*2*2 or *2*3) variant alleles compared to those with wild-type genotype (P<0.001). 
Regression analysis revealed that patient age (P=0.037) and CYP2C9 *2*2 & *2*3 genotype 
(P=0.005), but not VKORC1 genotype, significantly affected the time taken for the 
resumption of normal coagulation (INR value declining to ≤1.5).  
Conclusions                                                                                                                          
The inter-individual variability in the time needed for normal coagulation to resume following 
warfarin withdrawal is influenced, in the main, by variance in S-warfarin clearance, which in 
turn is affected by CYP2C9 polymorphism and age.  Cost-effectiveness of 
pharmacogenetics-based algorithms incorporating CYP2C9 genotype and patient age could 
be increased if used not only to guide dosing decisions but also estimation of the correct 
length of time needed for individual patients to stop taking warfarin prior to surgery. 
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Introduction  
Warfarin is prescribed as a 50:50 racemic mixture of (R)- and (S)- warfarin enantiomers, with 
the latter being 3-5 times pharmacologically more potent than the former. (S)-warfarin 
hydroxylation is influenced by polymorphisms in the CYP2C9 gene; CYP2C9*2 and 
CYP2C9*3 variants encoding enzymes that are respectively around 12% and 5% as efficient 
as the wild-type (CYP2C9 *1*1) enzyme (1-3). 
Vitamin K epoxide reductase, the pharmacological target enzyme for warfarin, recycles 
vitamin K epoxide to the reduced active form of vitamin K (vitamin K hydroquinone), an 
important cofactor needed in the functionalisation of clotting factors II, VII, IX, and X by –
glutamyl carboxylation of their N-terminals. The enzyme is encoded by the vitamin K epoxide 
reductase complex subunit 1 gene (VKORC1); polymorphisms in this gene have been 
identified and linked with clotting factor deficiencies and warfarin resistance (4) . 
Although the contribution of CYP2C9 and VKORC1 genotypes to warfarin dose 
requirements is well established (5-7), the extent of their influence upon the recognised inter 
individual variation in the rate of INR decay after cessation of warfarin therapy in patients 
awaiting surgery is not. An earlier study indicated that sensitivity to warfarin, advanced age 
and extreme elevation of the INR are independent risk factors for prolonged delay in return 
of a supra-therapeutic INR to the target range (8). In patients following established 
recommendations to stop their warfarin 5 days prior to an invasive procedure (9), rate of INR 
decline varies, with 23% having an INR >1.2 after 4.7 days of withdrawal from warfarin in 
one study (10), 7% having a pre-operative INR >1.5 after five days with subsequent need for 
vitamin K administration prior to surgery in another (11). In our previous study of the effect of 
CYP2C9 genotype upon INR decline, patients with two CYP2C9 variant alleles 
(CYP2C9*2*2 or CYP2C9*2*3) were found to be over 8 times more likely (95% (12) = 2.25–
33.25) to have an INR of ≥ 1.5 on the day before planned surgery, compared to those with 
either *1*1, *1*2 or *1*3 genotypes. The possible impact of VKORC1 polymorphism on the 
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fall in INR was not evaluated (13). The aim of the current study was to characterise further 
the contribution of genetic, patient and clinical factors toward warfarin elimination and its 
changing pharmacodynamics in patients with thromboembolic disease following warfarin 
withdrawal and to determine the potential clinical utility of a personalized pharmacogenetics-
based approach in guiding management of patients on warfarin scheduled for invasive 
surgery. 
Methods  
The study had the approval of the Newcastle upon Tyne Ethics Committee. All patients 
provided written informed consent according to the Declaration of Helsinki. One hundred and 
thirty five Caucasian patients aged over 18 years, completing a course of warfarin for 
indications of either venous thromboembolism (VTE), or atrial fibrillation (warfarin therapy 
stopped after successful cardioversion), with a target INR of 2.0-3.0 and stable control of 
anticoagulation (defined as having a stable warfarin dose for at least the previous 2 clinic 
visits a minimum of one week apart), were identified through the anticoagulant clinic records 
at the Newcastle upon Tyne Hospitals NHS Foundation Trust, UK. Any patient with a 
condition which might affect warfarin metabolism, notably congestive cardiac failure, 
hepatobiliary or renal disease or active cancer, taking medication known to interact with 
warfarin, or drinking more than the UK recommended safe limits (14 units per week for men 
and women) (14) was excluded. 
On the day of warfarin withdrawal, demographic data of age, weight, sex, and indication for 
anticoagulation therapy, medical diagnoses, daily warfarin dose, concomitant medication 
and alcohol intake were recorded. A blood sample (10ml) was taken for measurement of 
baseline INR and CYP2C9 and VKORC1 genotyping.  Thereafter, each patient attended the 
clinic on 3-4 separate occasions, spread over 9 days, beginning the day after their last dose 
of warfarin, with some variation to avoid scheduling conflicts (e.g. weekends) and missed 
appointments. A venous blood sample (10 ml) was collected at visit one (16-20 hours after 
the last dose of warfarin) for measurement of steady-state plasma warfarin enantiomer 
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concentrations and INR. A venous blood sample (10 ml) was taken at each of the remaining 
study visits for INR measurement only.  
Plasma warfarin enantiomer concentrations were determined by high performance liquid 
chromatography (HPLC) using the method of Naidong, et al (15). The limit of detection of the 
extracted samples was 2 ng/ml (signal/noise ratio =3). The inter-day coefficient of variation 
for S- and R- warfarin at 690 ng/ml was 4.2% and 3.8%, respectively. CYP2C9 and 
VKORC1 -1639 genotyping were carried out according to an established method (5). The 
rate of decline in INR for individual patients was determined from the slope of the plot of INR 
versus time. S- and R- warfarin clearance (CL) was calculated according to the formula: 
D/(2t X Css.av), where D is the daily dose of warfarin (mg), t is the dosing interval (24 
hours), and Css.av is the average steady-state plasma warfarin enantiomer concentration 
(mg/L), assuming that warfarin compliance and bioavailability are 100% (16). 
 
Sample size calculation  
According to previous studies INR reached a value of <1.5 in 74±19 hours following warfarin 
withdrawal (10, 11). To achieve 80% power and to detect a 15 hour difference in the time 
needed to reach an INR <1.5 between individuals with the CYP2C9 *1*1 genotype and 
either those with at least one variant allele (i.e. either CYP2C9*2 or CYP2C9*3) and allowing 
for the expected proportion in the three genotype groups, a sample size of 135 patients were 
needed to be studied. 
 
Statistical analysis 
Statistical analysis of the data was carried out using Minitab software version 17 (Coventry, 
UK). The effects of study variables on INR were assessed using multiple and logistic 
regression models. By regressing the logarithm of INR against time for each individual, the 
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time for INR to reach 1.5 was estimated. This estimated time was modelled using CYP2C9 
and VKORC1 genotypes, and other study variables. When necessary, data were 
transformed into their logarithmic values to approach normality. One-way analysis of 
variance (ANOVA) was used for comparison of continuous data. A P<0.05 was taken as 
being statistically significant. Data are presented as mean±SD unless otherwise stated. 
 
Results 
One hundred and thirty five patients were recruited into the study. However, for statistical 
analysis data were available for 131 participants [73 (56%) males] as four later withdrew 
from the study due to inability to attend study visits. The age range for the study cohort was 
21-92 years; there was no significant difference in mean age between males and females 
(62±15 versus 64±18 years). At the point of recruitment, patients were taking a median of 2 
drugs (IQR 1-5), excluding warfarin, 1 of which affected the cardiovascular system. Of drugs 
reported as potential inhibitors of CYP2C9, 1 patient was taking clopidogrel and 1 phenytoin, 
a drug which is also reported as a potential inducer of CYP2C9. Two patients were taking 
the potential inducer, carbamazepine. Forty one patients were taking statins of whom 30 
were taking simvastatin, 9 atorvastatin, 1 rosuvastatin and 1 pravastatin. No patient was 
taking amiodarone or fluvastatin.  As well as indications for warfarin (atrial fibrillation 11%, 
deep venous thrombosis 61%, pulmonary embolism 26%, and valvular prosthesis 2%), the 
median number of comorbidities was 1 (IQR 1-2), most commonly cardiovascular disease 
(69%). The frequency of CYP2C9 and VKORC1 genotypes in the study population are 
presented in Table 1.  
On the screening day following the final warfarin dose (warfarin dose usually taken early 
evening the day before), mean INR was 2.4±0.6. At the first study visit (16-20 hours after the 
last warfarin dose), the proportion of INR values ≥1.5 among those with CYP2C9 wild-type, 
single variant, and double variant genotype was 78%, 94%, and 100%, respectively; 
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CYP2C9 genotype was the only predictor of an INR <1.5 (P=0.009) at the first visit; the odds 
ratio for the single variant genotype relative to the wild-type was 0.22 (95%CI= 0.06, 0.79). 
The proportion of INR values ≥1.5 at the second visit (mean of 102 hours) among those with 
CYP2C9 wild-type, single- and double-variant alleles was 9%, 15%, and 40%, respectively, 
but these differences were no longer statistically significant; no further genetic influences 
were identifiable beyond the second visit as most of the INR values were close to 1.0 by the 
third and fourth study visits. 
According to regression analysis, which included the variables of VKORC1 and CYP2C9 
genotype, age, weight, sex, warfarin dose, comorbidities, concurrent drugs, and alcohol, 
CYP2C9 genotype was the only factor which influenced the rate of INR decline (P=0.014); 
the slope of the regression lines for INR for CYP2C9 (single and double variants) were 
significantly shallower than that for CYP2C9 wild-type.  Regression analysis revealed that 
the time required to fall to an INR value of 1.5 in patients initially within their 2-3 target range 
was significantly associated with both patient age (P=0.037) and CYP2C9 genotype 
(P=0.005) (R2=15.7%). Using the regression equation, it can be estimated that for example, 
a 90-year old will take 18 hours longer to reach an INR of 1.5 than a 30-year old, and, for 
example, at the age of 60, in patients with either *1*1, *1*2, *1*3, *2*2, or *2*3 genotype, on 
average it will take 61, 63, 78, 86, and 100 hours, respectively for the INR  to fall to 1.5. 
In patients possessing either a single or double CYP2C9 variant allele, S-warfarin clearance 
was slower (mean difference of 0.1 L/hour, for both single and double variant alleles; 
P<0.0001), compared to patients with wild-type genotype. Table 2 shows S- and R- warfarin 
clearance values for the various CYP2C9 genotypes. CYP2C9 genotype had no influence 
upon R-warfarin clearance. 
According to the regression analysis, neither VKORC1 genotype, concurrent therapy, co-
morbidity, patient weight, nor alcohol consumption influenced either the time taken for INR to 
reach 1.5, or S- and R- warfarin clearance.   
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As expected, warfarin weekly mean dose was significantly different between patients 
according to their CYP2C9 (p=0.0003) and VKORC1 (P<0.0001) genotype. Patients with 
CYP2C9 single- or double-variant alleles had a lower weekly mean dose requirement 
compared to the wild-type carriers; mean difference of 11mg (P=0.001) and 15 mg (P=0.03), 
respectively. Patients with VKORC1 AA or AG genotypes had lower weekly mean dose 
requirement compared to those with GG genotype; mean difference of 21 mg (P<0.0001) 
and 10 mg (P=0.003), respectively. Similarly, patients with VKORC1 AA genotype had a 
lower weekly mean dose requirement compared to those with AG genotype; mean difference 
11 mg, P=0.02. Also, as expected, warfarin weekly dose requirement was negatively 
correlated with age (r= -0.4, P<0.0001).  
 
Discussion 
Patients on warfarin are normally required to interrupt therapy for a fixed number of days 
prior to an invasive procedure. However, the anticoagulant activity of warfarin (as measured 
by INR) subsides at different rates among different patients. Discontinuation of warfarin too 
early may predispose the patient to thrombosis, and stopping it too late may result in peri-
operative bleeding. 
The results of this prospective study which investigated genetic and non-genetic influences 
upon INR decline support our hypothesis that the time required for the resumption of normal 
coagulation to take place following the cessation of warfarin therapy is largely dependent 
upon S-warfarin clearance, which in turn is influenced by CYP2C9 polymorphism and patient 
age (5). Polymorphisms in CYP2C9 (the main enzyme responsible for S-warfarin 
metabolism) and differences in patient age (which influences liver size and liver blood flow 
(17)) thus partly explain the previously reported variation in INR decay in patients 
withdrawing from warfarin prior to surgery (10, 11), accounting for 16% of the variability 
noted in this study. The influence of CYP2C9 on the fall in INR following warfarin withdrawal 
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observed in this study is in keeping with our previous study findings in that normalization of 
coagulation takes place more slowly in patients with CYP2C9 mutations, with those with two 
CYP2C9 variants being more than eight times more likely to have an INR of ≥ 1.5 on the fifth 
day of warfarin withdrawal (13). 
We also assessed the potential influence of VKORC1 polymorphism, based upon the notion 
that polymorphisms in VKOR, the pharmacological target for warfarin, can affect the fall in 
warfarin anticoagulant activity following warfarin cessation. However, VKORC1 
polymorphism made no significant contribution to the variability in INR decline in our study 
population. Two previous studies, one in healthy subjects (18), and the other in patients prior 
to surgery (19), found that neither VKORC1, nor CYP2C9, influenced the normalization of 
coagulation following warfarin withdrawal. However, neither study was sufficiently powered 
to detect the influence of either gene on the fall in INR; this was evident from the very small 
number of patients identified in either study as having variant alleles for VKORC1 and 
CYP2C9.  
In our self-reported Caucasian study population there were few patients who were of 
CYP2C9 *2*2* genotype, whilst there was only one patient who was of *2*3 genotype and no 
patient was of *3*3 genotype. As such, it was not possible to evaluate the effect of the 
individual genotypes on S-warfarin clearance and the fall in INR following warfarin 
withdrawal. Nevertheless, the frequency distribution for CYP2C9 genotype fits in with that of 
the Caucasian general population in whom only about 2% are homozygous and ~20% are 
heterozygous carriers of the CYP2C9*2 allele, with a significantly smaller proportion being 
either homozygous or heterozygous carriers of the CYP2C9*3 allele (20). In common with 
the literature we found that warfarin dose requirement was significantly influenced by 
CYP2C9 and VKROC1 genotype (5, 12, 21, 22). 
As well as S- warfarin, CYP2C9 has other drug substrates, some of which are potential 
inhibitors and some inducers of the enzyme (23, 24). Amiodarone is the most notable 
inhibitor, with a 22% reduction in predicted therapeutic dose having been associated with its 
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use in one study (25), 29% in another with a 12% lower warfarin dose requirement in 
patients who took simvastatin (26). Use of CYP2C9 inhibitors amiodarone, statins 
(simvastatin and fluvastatin), sulfamethoxazole, azole antifungals, and CYP2C9 inducers 
rifampicin, phenytoin and carbamazepine have also been reported by other studies (12, 25) 
to affect warfarin dose requirement. Of these drugs, only simvastatin was taken by some of 
our patients (30 out of 131; 22.9%). However, as there was no difference in the proportion of 
patients taking simvastatin between the wild-type (30.6%), single variant (35.4%) and double 
variant groups (14.3%), this would not have affected the generalisability of our findings.  
Whilst there is substantial evidence associating CYP2C9 and VKORC1 variants with 
warfarin dose requirements (5, 12, 20, 21), CYP2C9 is the more important gene determining 
initial anticoagulant control, with patients with mutant genes achieving a therapeutic INR 
faster than the wild-type ones (27). Many pharmacogenetics-based warfarin dosing 
algorithms have been developed for achieving a target INR of 2-3, the greatest potential for 
benefit for which is before initiation and early in the course of therapy (28-30). The GIFT 
randomized trial, the first of its kind powered to assess clinical outcomes, reported that use 
of a genotype-guided dosing algorithm for CYP2C9*2 and *3, CYP4F2*3 and VKORC1-1639 
versus a clinical dosing algorithm in elective hip and knee arthroplasty patients treated with 
perioperative warfarin resulted in a 27% reduction in the combined risk of major bleeding, 
INR of 4 or greater, venous thromboembolism, or death (31). 
Investigations of the cost-effectiveness of using pharmacogenetics-based information for 
warfarin therapy have historically considered initiation and continuation of warfarin, 
balancing the costs associated with genotyping against any reduction in adverse events over 
a fixed period, and have demonstrated inconsistent results. We set out in this study to 
investigate whether a pharmacogenetics-based algorithm incorporating CYP2C9 genotype 
and patient age could, in addition, be clinically useful for estimating the correct length of time 
needed for individual patients to stop taking warfarin prior to surgery, optimising the time 
patients spend off warfarin and thereby also potentially reducing the amount of interim 
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anticoagulation use with low molecular weight heparin given for high-risk patients while their 
INR is sub-therapeutic (9). This would be beneficial as, although such bridging therapy is 
associated with low rates of inpatient thromboembolism in elective general surgical patients, 
it is also associated with bleeding complications (32).  Our results, which demonstrate that 
CYP2C9 genotype does influence how quickly a patient withdrawing from warfarin will reach 
a safe INR before surgery indicate that including such genetic information into clinical 
practice has the potential to improve the cost-effectiveness of  temporary warfarin 
withdrawal, although as age and CYP2C9 genotype explained only 16% of variability, we 
conclude that establishing the extent of the influence of other factors both known to affect an 
individual’s response to warfarin such as disease states, diet and alcohol, and as yet 
unknown, would be required to improve the clinical applicability of this approach.  Future 
analyses of cost-effectiveness of pharmacogenetics-based algorithms incorporating both 
pharmacogenetics-guided dosing outcomes, and temporary withdrawal outcomes for 
patients in terms of the balance between savings made through reductions in the number of 
cancelled surgical procedures and thrombotic and bleeding complications, and the cost of 
genotyping, could guide health service providers in their decision making as to whether such 
an approach should be funded and incorporated into clinical practice.    
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Table 1: CYP2C9 and VKORC1 genotype frequency distribution in the study 
population  
CYP2C9 polymorphism, n (%)   
*1*1 72 (56.7) 
*1*2 33 (26.0) 
*1*3 15 (11.8) 
*2*2   6  (4.7) 
       *2*3   1  (0.8) 
VKORC1 polymorphism, (%)   
GG 49 (38.6) 
AG 63 (49.6) 
AA 15 (11.8) 
N.B. Genotyping data missing for 4 patients
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Table 2: Influence of CYP2C9 polymorphism on mean (SD) warfarin dose and 
clearance  
  Warfarin 
weekly dose 
(mg) 
Warfarin clearance (L/hr) 
  S R Racemic  
CYP2C9 polymorphism  
     
*1*1 40 (16) 0.20 (0.22) 0.07 (0.07) 0.11 (0.09) 
*1*2/*1*3 29 (14) 0.09 (0.04) 0.05 (0.04) 0.07 (0.03) 
*2*2/*2*3 25 (9) 0.09 (0.05) 0.07 (0.01) 0.07 (0.02) 
N.B. Data based on 127 patients as genotyping information was missing for 4 patients.  
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Highlights: 
 The fall in INR following warfarin withdrawal is influenced by CYP2C9 genotype and age. 
 
 VKORC1 genotype does not influence the rate of decline in INR following warfarin 
withdrawal. 
 
 A pharmacogenetic-guided approach could improve safety of temporary warfarin 
withdrawal prior to surgery. 
 
